Sunesis Pharma said that Vosaroxin is an anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer.
According to the company, the new patent is scheduled to expire on March 14, 2025, and could be eligible for patent term extension beyond this date.
Sunesis Pharma CEO Daniel Swisher said that this patent is an important new addition to their intellectual property estate, as it covers the formulation currently used in our clinical trials.
"Vosaroxin’s extended patent life to 2025 increases not only the value of our AML franchise but also provides sufficient time for lifecycle evaluation of Vosaroxin in other indications," Swisher said.
"In addition to our granted patents, we have filed patent applications covering additional formulations, combination uses, dosing, manufacturing processes and composition of matter claims.
"We look forward to the successful prosecution of these patent applications in multiple territories around the world."